On Thursday shares of Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) closed at $2.81. Ohr Pharmaceuticals, Inc. (NASDAQ: OHRP) recently announced disappointing top line results from the exploratory Phase II IMPACT study evaluating OHR-102 (0.2% Squalamine lactate ophthalmic solution) combination therapy for the treatment of the wet form of age-related macular degeneration (wet-AMD).
Cempra, Inc. (NASDAQ:CEMP) in last trading activity fell -6.72% to close at $31.49. Company weekly performance is -18.82% while its quarterly performance stands at 12.58%. Cempra, Inc. (NASDAQ:CEMP) is -24.36% away from its 52 week high. It was reported on 27 April, that Cempra Inc.(NASDAQ:CEMP) is in line for a $10 million milestone when the Japanese drug regulating authority processes a patent on Cempra’s experimental pneumonia treatment. This would be the second $10 milliontranche received by Cempra from Toyama Chemical Company, a subsidiary of FUJIFILM Holdings Corporation, though is still less than one-third of the total potential value of the partnership.
On last trading day Xenoport, Inc. (NASDAQ:XNPT) fell -9.05% to close at $5.93. Its volatility for the week is 8.44% while volatility for the month is 5.09%. XNPT’s sales growth for past 5 years was 6.50% and its EPS growth for past 5 years was 18.90%. Xenoport, Inc. (NASDAQ:XNPT) monthly performance is -16.71%. XenoPort Inc. (NASDAQ:XNPT) was upgraded by Zacks from a “hold” rating to a “buy” rating in a note issued to investors on Thursday.
Preferred Apartment Communities, Inc. (NYSEMKT:APTS) has 1.30% insider ownership while its institutional ownership stands at 37.60%. In last trading activity company’s stock closed at $11.06. Preferred Apartment Communities, Inc. (NYSEMKT:APTS) announced plans to release its first quarter 2015 earnings after the market closes on Monday, May 4, 2015.
On last trading day Neurocrine Biosciences Inc. (NASDAQ:NBIX) fell -8.19% to close at $34.09. Its volatility for the week is 8.93% while volatility for the month is 5.64%. NBIX’s EPS growth for past 5 years was 9.00%. Neurocrine Biosciences Inc. (NASDAQ:NBIX) monthly performance is -14.15%.Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Deutsche Bank 40th Annual Health Care Conference in Boston. The live presentation takes place on Thursday, May 7 at 11:20am ET (8:20am PT).